<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00193934</url>
  </required_header>
  <id_info>
    <org_study_id>TROG 04.02</org_study_id>
    <nct_id>NCT00193934</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer</brief_title>
  <official_title>Prospective Study to Determine the Relationships Between Survival and FIGO Stage, Tumour Volume and Corpus Invasion in Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trans-Tasman Radiation Oncology Group (TROG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peter MacCallum Cancer Centre, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Trans-Tasman Radiation Oncology Group (TROG)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers propose that it may be corpus invasion, rather than tumour volume per se,
      which is one of the important determinants of ultimate outcome in cervix cancer. The aim of
      the proposed prospective, multicentre study, is to confirm the results of our retrospective
      studies, specifically that corpus invasion or tumour volume or both contribute important
      prognostic information over and above that provided by the currently used International
      Federation of Gynecology and Obstetrics (FIGO) staging system. A successful outcome would
      have important implications for the staging, and management as well as the biologic
      understanding of the behaviour of cervical cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, multicentre, prognostic factor, follow-up study. The study is
      designed to be as simple as possible: newly diagnosed cervical cancer patients will have key
      prognostic variables collected at baseline. The treatment received will be documented at the
      end of treatment and patients will then be followed for first relapse and survival.

      Registration of a patient on this study can be undertaken after EUA, biopsy confirmed
      diagnosis, anatomic staging diagram and MRI have been done and before any treatment has
      commenced.

      Treatment must be curative in intent (termed radical therapy) but otherwise can be at the
      discretion of the investigator. Radical hysterectomy alone, hysterectomy followed by adjuvant
      radiotherapy, radical chemo-radiotherapy or radical radiotherapy will be allowed. Details of
      the planned and given treatment regimen will be recorded.

      All patients will have the following trial data documented at the time of registration:

        -  Age

        -  ECOG performance status

        -  smoking status

        -  date of histological diagnosis

        -  histologic type and features

        -  presenting haemoglobin

        -  standard FIGO staging

        -  maximum clinical tumour diameter measured at EUA

        -  detailed staging diagram drawn at EUA

        -  nodal status (by surgical pathology or CT or MRI or both and PET if available)

        -  date of MRI

        -  MRI tumour diameters

        -  presence or absence of corpus invasion on MRI

        -  planned treatment details

      All patients will be assessed pre-treatment, immediately following treatment and will be
      followed up for local control and survival at yearly intervals from the date of registration.

      It is intended to collect follow up information on all patients until one year after the
      final patient is registered on study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 15, 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the prognostic significance, with respect to overall survival, of the factors, FIGO stage. Overall survival is defined as the date of registration to date of death from any cause.</measure>
    <time_frame>End of study</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">109</enrollment>
  <condition>Cancer of the Uterine Cervix</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Cervical Cancer Patients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed cervical cancer patients, Female
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed, biopsy proven carcinoma of the uterine cervix.

          2. Squamous cell, adenocarcinoma, adenosquamous or large cell carcinoma histology.

          3. FIGO Stage Ib -IVa.

          4. Maximum clinical tumour diameter recorded.

          5. MRI done within 30 days prior to registration.

          6. Intention to treat radically

          7. Treatment not yet started.

          8. Written informed consent.

          9. Available for follow-up.

        Exclusion Criteria:

          1. Lymphoma, small cell carcinoma and melanoma histology.

          2. Previous hysterectomy

          3. Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Adams</last_name>
    <role>Study Chair</role>
    <affiliation>Oceania Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>1871</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2069</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Wentworthville</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Queensland Oncology Service</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4810</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premion - Tugun</name>
      <address>
        <city>Tugun</city>
        <state>Queensland</state>
        <zip>4224</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meenakshi Mission Hospital</name>
      <address>
        <city>Tamil Nadu</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1001</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>4710</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>India</country>
    <country>New Zealand</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.trog.com.au</url>
    <description>Click here for more information about this study on the TROG official website</description>
  </link>
  <reference>
    <citation>Narayan K, McKenzie A, Fisher R, Susil B, Jobling T, Bernshaw D. Estimation of tumor volume in cervical cancer by magnetic resonance imaging. Am J Clin Oncol. 2003 Oct;26(5):e163-8.</citation>
    <PMID>14528092</PMID>
  </reference>
  <reference>
    <citation>Narayan K, McKenzie AF, Hicks RJ, Fisher R, Bernshaw D, Bau S. Relation between FIGO stage, primary tumor volume, and presence of lymph node metastases in cervical cancer patients referred for radiotherapy. Int J Gynecol Cancer. 2003 Sep-Oct;13(5):657-63.</citation>
    <PMID>14675351</PMID>
  </reference>
  <reference>
    <citation>Narayan K. Arguments for a magnetic resonance imaging-assisted FIGO staging system for cervical cancer. Int J Gynecol Cancer. 2005 Jul-Aug;15(4):573-82. Review.</citation>
    <PMID>16014109</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Trans-Tasman Radiation Oncology Group (TROG)</investigator_affiliation>
    <investigator_full_name>TROG Administrator</investigator_full_name>
    <investigator_title>Rebecca Montgomery</investigator_title>
  </responsible_party>
  <keyword>Women's Health</keyword>
  <keyword>Multidisciplinary, multicentre prospective study</keyword>
  <keyword>Cancer:mechanisms of growth, invasion, metastases</keyword>
  <keyword>Figo Stages cervical cancer</keyword>
  <keyword>Advances in diagnosis using radiological methods</keyword>
  <keyword>Quantitative Magnetic Resonance Imaging</keyword>
  <keyword>Patient Management Strategies</keyword>
  <keyword>Selecting patients for therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

